




PHARMACEUTICAL 2018

Tonix Pharmaceuticals Holding Corp.
Rank 122 of 342





RealRate

PHARMACEUTICAL 2018

Tonix Pharmaceuticals Holding Corp. Rank 122 of 342

The relative strengths and weaknesses of Tonix Pharmaceuticals Holding Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tonix Pharmaceuticals Holding Corp. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 116% points. The greatest weakness of Tonix Pharmaceuticals Holding Corp. is the variable Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 147%, being 101% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	26,443
Cost of Goods Sold	0
Intangible Assets	120
Liabilities, Current	2,126
Liabilities, Non-Current	0
Other Assets	100
Other Compr. Net Income	-5.0
Other Expenses	0
Other Liabilities	12
Other Net Income	168
Other Revenues	0
Property and Equipment	91
Research and Development	13,342
Selling, General and Administrative Expense	7,949

Output Variable	Value in 1000 USD
Assets	26,754
Liabilities	2,138
Expenses	21,291
Revenues	0
Stockholders Equity	24,616
Net Income	-21,123
Comprehensive Net Income	-21,126
Economic Capital Ratio	147%